 Jessica Cardenas
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thromboembolism | 11 | 2024 | 324 | 4.760 |
Why?
| | Thrombosis | 12 | 2026 | 393 | 4.000 |
Why?
| | Wounds and Injuries | 27 | 2026 | 957 | 3.980 |
Why?
| | Shock, Hemorrhagic | 9 | 2026 | 201 | 3.480 |
Why?
| | Blood Coagulation Disorders | 12 | 2025 | 189 | 3.220 |
Why?
| | Hemostasis | 14 | 2026 | 102 | 3.030 |
Why?
| | Endothelial Cells | 9 | 2026 | 870 | 2.220 |
Why?
| | Thrombin | 15 | 2026 | 166 | 2.020 |
Why?
| | Thrombophilia | 4 | 2022 | 88 | 1.510 |
Why?
| | Enoxaparin | 3 | 2022 | 67 | 1.450 |
Why?
| | Fibrinolysis | 7 | 2025 | 162 | 1.440 |
Why?
| | Endothelium, Vascular | 8 | 2026 | 965 | 1.430 |
Why?
| | Antithrombins | 4 | 2025 | 70 | 1.370 |
Why?
| | Blood Transfusion | 9 | 2026 | 405 | 1.360 |
Why?
| | Syndecan-1 | 6 | 2023 | 43 | 1.250 |
Why?
| | Thrombelastography | 17 | 2026 | 178 | 1.240 |
Why?
| | Blood Coagulation | 12 | 2025 | 268 | 1.150 |
Why?
| | Fibrinogen | 6 | 2026 | 177 | 0.990 |
Why?
| | Antithrombin III | 3 | 2022 | 17 | 0.980 |
Why?
| | Hemorrhage | 7 | 2023 | 809 | 0.890 |
Why?
| | Blood Component Transfusion | 6 | 2021 | 103 | 0.840 |
Why?
| | von Willebrand Factor | 2 | 2025 | 85 | 0.810 |
Why?
| | Plasma | 2 | 2026 | 225 | 0.750 |
Why?
| | Cadherins | 2 | 2023 | 201 | 0.740 |
Why?
| | Platelet Transfusion | 2 | 2019 | 80 | 0.660 |
Why?
| | Shock | 2 | 2021 | 108 | 0.660 |
Why?
| | Inflammation | 7 | 2026 | 2880 | 0.640 |
Why?
| | Blood Platelets | 7 | 2022 | 400 | 0.630 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 439 | 0.620 |
Why?
| | Brain Injuries, Traumatic | 6 | 2025 | 441 | 0.590 |
Why?
| | Plasminogen Activator Inhibitor 1 | 3 | 2019 | 84 | 0.590 |
Why?
| | alpha-2-Antiplasmin | 2 | 2019 | 3 | 0.580 |
Why?
| | Periodicals as Topic | 1 | 2021 | 203 | 0.560 |
Why?
| | Humans | 67 | 2026 | 144957 | 0.540 |
Why?
| | Anticoagulants | 5 | 2023 | 724 | 0.530 |
Why?
| | Cell-Derived Microparticles | 2 | 2015 | 75 | 0.510 |
Why?
| | Prospective Studies | 17 | 2025 | 7997 | 0.490 |
Why?
| | Injury Severity Score | 10 | 2025 | 600 | 0.480 |
Why?
| | Capillary Permeability | 3 | 2023 | 134 | 0.450 |
Why?
| | Endothelial Progenitor Cells | 1 | 2015 | 20 | 0.440 |
Why?
| | Fibrinolysin | 1 | 2014 | 19 | 0.420 |
Why?
| | Male | 39 | 2026 | 72406 | 0.410 |
Why?
| | Adult | 32 | 2026 | 40506 | 0.400 |
Why?
| | Rats, Sprague-Dawley | 5 | 2025 | 2540 | 0.400 |
Why?
| | Middle Aged | 30 | 2026 | 35928 | 0.390 |
Why?
| | Tissue Plasminogen Activator | 2 | 2017 | 244 | 0.390 |
Why?
| | Hemostatics | 2 | 2023 | 61 | 0.360 |
Why?
| | Inflammation Mediators | 2 | 2025 | 509 | 0.350 |
Why?
| | Obesity, Morbid | 1 | 2015 | 281 | 0.330 |
Why?
| | Thrombomodulin | 4 | 2025 | 15 | 0.320 |
Why?
| | Rats | 4 | 2025 | 5614 | 0.310 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2015 | 372 | 0.310 |
Why?
| | Glycocalyx | 3 | 2019 | 30 | 0.290 |
Why?
| | Female | 32 | 2026 | 78376 | 0.260 |
Why?
| | Animals | 12 | 2026 | 38109 | 0.260 |
Why?
| | Postoperative Complications | 2 | 2023 | 2920 | 0.260 |
Why?
| | Blood Coagulation Tests | 5 | 2025 | 70 | 0.260 |
Why?
| | Risk Factors | 8 | 2025 | 10792 | 0.260 |
Why?
| | Fibrin | 3 | 2023 | 91 | 0.260 |
Why?
| | Factor VIII | 2 | 2026 | 104 | 0.250 |
Why?
| | Resuscitation | 4 | 2023 | 302 | 0.250 |
Why?
| | Radiobiology | 1 | 2026 | 7 | 0.250 |
Why?
| | Cohort Studies | 5 | 2022 | 5965 | 0.240 |
Why?
| | Blood Preservation | 2 | 2021 | 354 | 0.240 |
Why?
| | Endothelium | 2 | 2023 | 119 | 0.230 |
Why?
| | Radiation Oncology | 1 | 2026 | 89 | 0.230 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2023 | 93 | 0.230 |
Why?
| | Retrospective Studies | 7 | 2024 | 17101 | 0.220 |
Why?
| | Interleukin-8 | 2 | 2023 | 271 | 0.220 |
Why?
| | Interleukin-6 | 3 | 2025 | 780 | 0.220 |
Why?
| | Oxidative Stress | 2 | 2025 | 1339 | 0.210 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 57 | 0.210 |
Why?
| | Blood Donors | 1 | 2026 | 143 | 0.210 |
Why?
| | Platelet Function Tests | 6 | 2022 | 34 | 0.210 |
Why?
| | Mice, Inbred C57BL | 3 | 2026 | 5997 | 0.200 |
Why?
| | Coagulants | 1 | 2023 | 20 | 0.200 |
Why?
| | Endothelial Protein C Receptor | 1 | 2023 | 6 | 0.200 |
Why?
| | Sulfates | 1 | 2023 | 49 | 0.190 |
Why?
| | Platelet Aggregation | 5 | 2022 | 105 | 0.190 |
Why?
| | Chemokines | 1 | 2023 | 218 | 0.190 |
Why?
| | Chemoprevention | 1 | 2023 | 90 | 0.180 |
Why?
| | Biomarkers | 10 | 2026 | 4275 | 0.180 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2023 | 95 | 0.180 |
Why?
| | Lung Injury | 1 | 2025 | 237 | 0.170 |
Why?
| | Extracellular Vesicles | 2 | 2025 | 171 | 0.170 |
Why?
| | Venous Thrombosis | 1 | 2023 | 195 | 0.170 |
Why?
| | Pulmonary Embolism | 1 | 2023 | 244 | 0.170 |
Why?
| | Infusion Pumps | 1 | 2020 | 32 | 0.170 |
Why?
| | Sarcoidosis | 1 | 2023 | 160 | 0.170 |
Why?
| | Endovascular Procedures | 1 | 2025 | 384 | 0.160 |
Why?
| | Mice | 5 | 2026 | 18365 | 0.160 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.150 |
Why?
| | Publishing | 1 | 2021 | 114 | 0.150 |
Why?
| | Catecholamines | 2 | 2017 | 87 | 0.150 |
Why?
| | Time Factors | 5 | 2025 | 7183 | 0.150 |
Why?
| | Neutrophil Infiltration | 1 | 2020 | 104 | 0.150 |
Why?
| | Cells, Cultured | 2 | 2025 | 4155 | 0.150 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2023 | 292 | 0.150 |
Why?
| | Multiple Trauma | 1 | 2020 | 116 | 0.140 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2022 | 497 | 0.140 |
Why?
| | Mitochondria | 1 | 2025 | 984 | 0.140 |
Why?
| | Peripheral Arterial Disease | 1 | 2025 | 503 | 0.140 |
Why?
| | Cytokines | 1 | 2025 | 2065 | 0.130 |
Why?
| | Serum Albumin | 1 | 2018 | 147 | 0.130 |
Why?
| | Blood Coagulation Factors | 3 | 2026 | 55 | 0.130 |
Why?
| | Incidence | 1 | 2024 | 2883 | 0.130 |
Why?
| | E-Selectin | 1 | 2017 | 61 | 0.130 |
Why?
| | Intracranial Hemorrhages | 1 | 2017 | 100 | 0.130 |
Why?
| | Electric Injuries | 1 | 2016 | 2 | 0.130 |
Why?
| | Adrenal Glands | 1 | 2017 | 77 | 0.120 |
Why?
| | Burns, Electric | 1 | 2016 | 26 | 0.120 |
Why?
| | Disease-Free Survival | 1 | 2018 | 769 | 0.120 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4569 | 0.120 |
Why?
| | Transcriptome | 1 | 2023 | 1046 | 0.120 |
Why?
| | RNA | 1 | 2023 | 940 | 0.120 |
Why?
| | Sympathetic Nervous System | 1 | 2017 | 178 | 0.120 |
Why?
| | Energy Drinks | 1 | 2015 | 3 | 0.110 |
Why?
| | Platelet Count | 3 | 2021 | 96 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2020 | 576 | 0.110 |
Why?
| | Aged | 7 | 2025 | 25947 | 0.110 |
Why?
| | Apoptosis | 2 | 2025 | 2430 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1217 | 0.110 |
Why?
| | Cysteine-Rich Protein 61 | 1 | 2014 | 7 | 0.110 |
Why?
| | Fluid Therapy | 1 | 2016 | 147 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2017 | 251 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2023 | 927 | 0.100 |
Why?
| | Lung | 2 | 2025 | 4109 | 0.100 |
Why?
| | Blood Specimen Collection | 1 | 2014 | 38 | 0.100 |
Why?
| | Protein C | 1 | 2014 | 53 | 0.100 |
Why?
| | Cell Line | 1 | 2020 | 2882 | 0.100 |
Why?
| | Emergency Medical Services | 1 | 2021 | 696 | 0.100 |
Why?
| | Wounds, Nonpenetrating | 1 | 2017 | 316 | 0.100 |
Why?
| | Hemostatic Techniques | 1 | 2014 | 51 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 2092 | 0.100 |
Why?
| | Texas | 1 | 2014 | 278 | 0.100 |
Why?
| | Case-Control Studies | 3 | 2016 | 3608 | 0.100 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2014 | 319 | 0.090 |
Why?
| | Homeostasis | 1 | 2016 | 640 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2018 | 851 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 1087 | 0.080 |
Why?
| | Neoplasms | 1 | 2026 | 2884 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2118 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2925 | 0.070 |
Why?
| | Prognosis | 4 | 2019 | 4293 | 0.070 |
Why?
| | Young Adult | 7 | 2019 | 14126 | 0.070 |
Why?
| | Trauma Severity Indices | 2 | 2018 | 112 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2014 | 2499 | 0.060 |
Why?
| | Color | 1 | 2026 | 81 | 0.060 |
Why?
| | Cell Adhesion Molecules | 1 | 2025 | 178 | 0.050 |
Why?
| | Trauma Centers | 2 | 2017 | 462 | 0.050 |
Why?
| | Calcium-Binding Proteins | 1 | 2025 | 220 | 0.050 |
Why?
| | Longitudinal Studies | 2 | 2026 | 2947 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2023 | 36 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2025 | 455 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2025 | 8279 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1540 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1890 | 0.050 |
Why?
| | Medical Futility | 1 | 2023 | 31 | 0.050 |
Why?
| | Biology | 1 | 2023 | 91 | 0.050 |
Why?
| | Reference Standards | 1 | 2023 | 178 | 0.050 |
Why?
| | Heparin | 1 | 2023 | 244 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2025 | 621 | 0.050 |
Why?
| | Vital Capacity | 1 | 2023 | 290 | 0.050 |
Why?
| | Immunomodulation | 1 | 2023 | 101 | 0.040 |
Why?
| | Cell Separation | 1 | 2023 | 307 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2014 | 2456 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 87 | 0.040 |
Why?
| | Logistic Models | 2 | 2017 | 2119 | 0.040 |
Why?
| | Genomics | 1 | 2026 | 836 | 0.040 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2020 | 29 | 0.040 |
Why?
| | B7-H1 Antigen | 1 | 2023 | 241 | 0.040 |
Why?
| | Metabolomics | 1 | 2026 | 727 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2026 | 916 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2020 | 116 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2023 | 1173 | 0.040 |
Why?
| | Cold Temperature | 1 | 2020 | 209 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1195 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1048 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 735 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3125 | 0.030 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2017 | 24 | 0.030 |
Why?
| | Edema | 1 | 2018 | 124 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 405 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2025 | 11695 | 0.030 |
Why?
| | Neutrophils | 1 | 2023 | 1134 | 0.030 |
Why?
| | Antifibrinolytic Agents | 1 | 2017 | 62 | 0.030 |
Why?
| | Platelet Adhesiveness | 1 | 2016 | 15 | 0.030 |
Why?
| | Epinephrine | 1 | 2017 | 155 | 0.030 |
Why?
| | Norepinephrine | 1 | 2017 | 196 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 582 | 0.030 |
Why?
| | Kaolin | 1 | 2015 | 5 | 0.030 |
Why?
| | Risk Assessment | 1 | 2025 | 3676 | 0.030 |
Why?
| | Methionine | 1 | 2016 | 162 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2015 | 101 | 0.030 |
Why?
| | ROC Curve | 1 | 2017 | 615 | 0.030 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2014 | 10 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2015 | 215 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 854 | 0.030 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 50 | 0.030 |
Why?
| | Punctures | 1 | 2014 | 40 | 0.030 |
Why?
| | Random Allocation | 1 | 2015 | 363 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 69 | 0.030 |
Why?
| | 3T3 Cells | 1 | 2014 | 156 | 0.030 |
Why?
| | Forkhead Box Protein O1 | 1 | 2014 | 36 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2014 | 135 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1054 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1385 | 0.020 |
Why?
| | Solubility | 1 | 2014 | 242 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2014 | 249 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 202 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1325 | 0.020 |
Why?
| | Femoral Artery | 1 | 2014 | 190 | 0.020 |
Why?
| | Forecasting | 1 | 2014 | 391 | 0.020 |
Why?
| | Reference Values | 1 | 2014 | 798 | 0.020 |
Why?
| | Adolescent | 3 | 2017 | 22453 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1721 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 311 | 0.020 |
Why?
| | Hospitalization | 1 | 2023 | 2434 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1990 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2017 | 1031 | 0.020 |
Why?
| | Burns | 1 | 2016 | 377 | 0.020 |
Why?
| | Liver | 1 | 2019 | 1888 | 0.020 |
Why?
| | Cardiac Catheterization | 1 | 2014 | 560 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 965 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7191 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1822 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2836 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3415 | 0.010 |
Why?
| | Phenotype | 1 | 2014 | 3164 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2015 | 6434 | 0.010 |
Why?
| | Infant | 1 | 2015 | 10039 | 0.010 |
Why?
| | Child, Preschool | 1 | 2015 | 11799 | 0.010 |
Why?
| | United States | 1 | 2014 | 15988 | 0.010 |
Why?
| | Child | 1 | 2015 | 22657 | 0.010 |
Why?
|
|
Cardenas's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|